G6PD and chloroquine: Selecting the treatment against SARS-CoV-2?

Kassi, Eva N; Papavassiliou, Kostas A; Papavassiliou, Athanasios G

Kassi, Eva N; Papavassiliou, Kostas A; Papavassiliou, Athanasios G.

Kassi EN; Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Papavassiliou KA; Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Papavassiliou AG; Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

J Cell Mol Med ; 24(9): 4913-4914, 2020 05.

Article in English | MEDLINE | ID: covidwho-1388304

Subject(s)

Chloroquine/adverse effects; Betacoronavirus/physiology; Coronavirus Infections/drug therapy; Glucosephosphate Dehydrogenase/metabolism; Glucosephosphate Dehydrogenase Deficiency/complications; Humans; SARS-CoV-2; COVID-19 Drug Treatment

Keywords

COVID-19 (SARS-CoV-2); G6PD; chloroquine; haemolysis; oxidative injury; pandemic; retinopathy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chloroquine Topics: Long Covid Limits: Humans Language: English Journal: J Cell Mol Med Journal subject: Molecular Biology Year: 2020 Document Type: Article Affiliation country: JCMM.15312

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google